• 검색 결과가 없습니다.

The release of viral particle from hepatitis B virus infected hepatocytes is inhibited by recombinant hepatitis B virus immunoglobulin (lenvervimab)

N/A
N/A
Protected

Academic year: 2021

Share "The release of viral particle from hepatitis B virus infected hepatocytes is inhibited by recombinant hepatitis B virus immunoglobulin (lenvervimab)"

Copied!
1
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

AHBPSAnnals of Hepato-Biliary-Pancreatic Surgery

www.ahbps.org S228

The release of viral particle from hepatitis B virus infected hepatocytes is inhibited by recombinant

hepatitis B virus immunoglobulin (lenvervimab)

Kyung Chul YOON, Kwang-Woong LEE*, SooIn SEO, Seung Cheol OH, Min-Young PARK, Suk Kyun HONG, Jeong-Moo LEE, Nam-Joon YI, Kyung-Suk SUH

Department of Surgery, Seoul National University College of Medicine, Seoul, Korea

EP-27

Introduction: Potent and relatively low cost hepatitis B immunoglobulin (HBIG) could be good alternatives by overcoming the drawbacks of recent regimen and recombinant monoclonal HBIG (lenvervimab) has been reported the consistent avidity of variety to cloned S antigens including the immune escape mutant G145R and it did not interfere with the antibody binding in hepatitis B virus (HBV) with mutations of the S gene sequence which makes drug resistance to NA. We investigated the action of intracellularly located lenvervimab in HBV infected cells which is incompletely understood yet.

Methods: We used five human hepatoma cell lines; Huh7, HepG2 as HBV negative and PLC/PRF/5, HepG2.2.15, and Hep3B express- ing HBsAg. and various intracellular orgarnells markers; endosome (Rab5), autophagy marker (LC3) , anti-calnexin (ER), giantin (gol- gi), multivesicular body (Rab7). Immunofluorescence images were used to investigate the intracellular locations of lenvervimab and HBsAg. Western blot and PEG down, ELISA were used for protein analysis.

Results: Lenvervimab was co-localized with Rab5 (early endosome marker) and and induces autophagosome but not autolysis. HBsAg and Lenvervimab were co-localized with making precipitations in cytoplasm and these precipitations were not co-localized with ER and golgi marker. Rab7 (multivesicular body marker) and lenvervimab, HBsAg were co-localized in PLC/PRF/5.

Conclusions: The release of viral particle is suppressed by lenvervimab with antigen-antibody reaction in multivesicular body.

pISSN: 2508-5778ㆍeISSN: 2508-5859

Ann Hepatobiliary Pancreat Surg 2021;25 Suppl 1:S228 https://doi.org/10.14701/ahbps.EP-27

Corresponding Author: Kwang-Woong LEE ([email protected]) Presenter: Kyung Chul YOON ([email protected])

Copyright Ⓒ The Korean Association of Hepato-Biliary-Pancreatic Surgery

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

참조

관련 문서

https://quizlet.com/_8gkp6x?x=1qqt&i=2tig8t 첨부한 프린트 자ㅊ ㄹㅎ료를 미리 부모님들께보내주세요.. 온라인 수업에 아이들 이

A smaller value of the starting relaxation order ω = ω max given by (17) for the sparse PSDP formulation (7) than the sparse POP formulation (3), as shown in Section 4, does

This model is a generalization of the standard quadratic optimization problem of minimizing a quadratic form over the standard simplex, and covers many of the

Numerical results in Section 5 show that the proposed method outperforms SFSDP for uniformly sparse EDGPs, and produces comparable results to DISCO for molecular

We present numerical methods, including the bisection and projection method [19], for solving the the Lagrangian-conic relaxation and its dual (7) and (8) in Section 4, and

Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines. Adult immu- nization schedule recommended

Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg(+) chronic hepatitis B (CHB) infection: observations from antiviral-naïve patients

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind,